>>> US Research Calls II

Research Calls II
  • Upgrades:
    • CareDx (CDNA) upgraded to Buy from Neutral at BTIG Research; tgt $40
    • Newmont Corporation (NEM) upgraded to Sector Outperform from Sector Perform at Scotiabank; tgt raised to $59
  • Downgrades:
    • AngloGold Ashanti (AU) downgraded to Sector Underperform from Sector Perform at Scotiabank; tgt raised to $30
    • Codexis (CDXS) downgraded to Hold from Buy at The Benchmark Company
    • Chuy's (CHUY) downgraded to Hold from Buy at The Benchmark Company; tgt $37.50
    • Gogoro (GGR) downgraded to Hold from Buy at The Benchmark Company
    • Hamilton Insurance Group, Ltd. (HG) downgraded to Equal-Weight from Overweight at Morgan Stanley; tgt $19
  • Others:
    • Apple (AAPL) initiated with a Neutral at MoffettNathanson; tgt $211
    • Athira Pharma (ATHA) initiated with a Buy at Rodman & Renshaw; tgt $22
    • Concentra Group Holdings Parent (CON) initiated with a Buy at Truist; tgt $29
    • Concentra Group Holdings Parent (CON) initiated with an Overweight at Wells Fargo; tgt $27
    • Concentra Group Holdings Parent (CON) initiated with an Outperform at Mizuho; tgt $28
    • Concentra Group Holdings Parent (CON) initiated with a Buy at Goldman; tgt $32
    • Concentra Group Holdings Parent (CON) initiated with an Overweight at JP Morgan; tgt $29
    • Concentra Group Holdings Parent (CON) initiated with a Buy at Deutsche Bank; tgt $29
    • HEICO (HEI) initiated with an Equal Weight at Barclays; tgt $250
    • Lineage (LINE) initiated with a Hold at Deutsche Bank; tgt $90
    • Lineage (LINE) initiated with an Overweight at Piper Sandler; tgt $102
    • OneStream (OS) initiated with a Buy at Needham; tgt $33
    • OneStream (OS) initiated with a Buy at BofA Securities; tgt $35
    • OneStream (OS) initiated with a Buy at TD Cowen; tgt $34
    • OneStream (OS) initiated with a Buy at Loop Capital; tgt $35

>>> US Gapping down

Gapping down
In reaction to earnings/guidance
:
  • EL -3.1%
Other news:
  • LQDA -38.8% (receives tentative approval from FDA for YUTREPIA Inhalation Powder)
  • RILY -13% (receives unsolicited preliminary proposal to be taken private at $7.00/share)
  • VCEL -1.9% (files mixed shelf securities offering)
  • CSIQ -1.7% (enters into definitive agreement with PAG pursuant to which PAG will subscribe for $200 million in aggregate principal amount of convertible notes to be issued by the company)
  • KEN -1.3% (announces entry into agreements for equity investment in its U.S. renewable energy business; also announces commencement of construction of CPV Group wind project)
Analyst comments:
  • BROS -3% (downgraded to Neutral from Overweight at Piper Sandler)
  • SHAK -3% (downgraded to Neutral from Overweight at Piper Sandler)
  • HPQ -2.1% (downgraded to Equal-Weight from Overweight at Morgan Stanley)

>>> US Gapping up

Gapping up
News:
  • XPER +20.1% (subsidiary Perceive Corporation to be sold to Amazon (AMZN) for $80 mln in cash)
  • SOND +16.8% (secured deals to raise capital and integrate brand with Marriott (MAR), according to Bloomberg)
  • FUBO +13.7% (wins preliminary injunction against Venu Sports joint venture between DIS, FOXA, and WBD) BNR +8.4% (intends to delist ADSs on London Stock Exchange)
  • CVII +7.7% (Churchill Capital Corp VII and CorpAcq mutually agree to terminate business combination)
  • FULC +2.7% (Strengthens Leadership Team with the Appointments of Isabel Kalofonos as Chief Commercial Officer and Heather Faulds as Chief Regulatory Affairs & Quality Assurance Officer)
  • AMD +2.3% (announced the signing of a definitive agreement to acquire ZT Systems in a cash and stock transaction valued at $4.9 bln)
  • INVE +2.2% (Announces Security Business Asset Sale Transaction Receives CFIUS Clearance)
  • GLAD +1.2% (discloses it entered into equity distribution agreement)
Analyst comments:
  • GTES +2.6% (upgraded to Outperform from Sector Perform at RBC Capital Mkts)
  • TMHC +2% (upgraded to Buy from Neutral at BTIG Research)
  • BURL +1.4% (upgraded to Buy from Hold at Gordon Haskett)

FT Lex : Copycat weight-loss drugs are becoming big business

Copycat weight-loss drugs are becoming big business
Hims & Hers’ shares shot up after it said it would start selling a version of Wegovy

Pop quiz: what is the best-performing obesity drug play over the past 12 months? The obvious answer would be Novo Nordisk or Eli Lilly. But that would be wrong.

The two companies, which dominate the class of GLP-1 weight-loss treatments, have done well. But Hims & Hers Health, a telehealth company that started selling compounded — or copycat — versions of these drugs, has done even better. Shares in the San Francisco-based start-up are up more than 120 per cent since last August. Eli Lilly has gained 67 per cent and Novo 44 per cent. 

True, Hims, which got its start selling erectile dysfunction and hair-loss medications, is a much smaller company, with a market value of under $3.5bn. The shares were also coming off a low base. Eli Lilly is worth $876bn while Novo is a more than DKr3tn ($443bn) company.

Still, Hims’ sharp share price rally underscores how explosive demand, coupled with a supply shortage of Wegovy, Ozempic, Zepbound and other GLP-1 drugs, has created a massive business opportunity for compounded drugmakers and sellers.


Compounded drugs are not generics. They are copies. They are made with the same basic ingredient as branded drugs but by a specialised pharmacy, not a drug company. They do not have Food and Drug Administration approval. Nor, as rival digital health start-up Ro explains in a disclaimer on its website, “do they require safety, effectiveness, or manufacturing review”.

However, they are allowed to be made when there is a shortage. That is the case with GLP-1 weight-loss drugs, which work by mimicking a hormone produced in the gut to suppress a person’s appetite and regulate blood sugar.

Founded in 2017, Hims went public just four years later via a Spac deal. The company has yet to make a profit. It reported a net loss of $23.5mn on revenues of $872mn last year. The stock spent most of 2021 through 2023 trading below its $10 initial price. 

But the shares shot up after it said in May it would start selling a version of Wegovy. It followed that up this month with news that it was buying a compounded pharmacy to help lock up supply. Investors lapped it up. The demand for GLP-1 drugs appears insatiable. Hims’ version, starting at just $199 a month, is substantially cheaper than the $1,000 or more out of pocket for the branded version.

This is a controversial area, with safety and effectiveness the main concerns. Both Novo and Lilly have filed numerous lawsuits to try to stop the sale of compounded versions of their drugs. Then there is the question of what happens once the branded drug shortage eases. Investors who have bid up the stock this year could be left holding the bag.

FT : Can a streaming underdog succeed against ESPN, Fox and Warner Bros?

Can a streaming underdog succeed against ESPN, Fox and Warner Bros?
FuboTV sued the trio arguing their joint venture was anti-competitive and the judge has temporarily agreed

FuboTV is a distinct underdog in the streaming wars, with fewer than 2mn US customers. For its base $80 a month plan, customers can stream hundreds of channels, yet most are interested in the handful of brand-name networks that show sports matches. 

But on Friday, this little-known company pulled off an epic upset.

A New York federal district court issued an injunction keeping three industry heavyweights — Disney’s ESPN, Fox and Warner Bros Discovery — from launching a specialist sports-only streamer, only weeks before its intended debut. Fubo had argued in a lawsuit that the joint venture, called Venu, was anti-competitive and the judge has temporarily agreed. 

For Fubo, there is little time to celebrate. Its annual revenue is under $2bn, its market capitalisation is down to $500mn and it is spending precious cash to buy back convertible bonds that come due in less than two years.

Disney, Fox and WBD had planned for Venu to cost just $43 a month at the outset. No doubt Fubo would love to slash its price in half to keep up. But the likes of Disney force Fubo to buy not just ESPN — whose wholesale cost to distributors can be as much as $9 a month — but other unpopular networks that require subsidy. 

Fubo sued the trio under the theory that they created Venu to carry sports channels only, an “unbundled” arrangement not offered to Fubo. The judge agreed that this disparate treatment was enough to issue an injunction before a full trial.

Disney, Fox and WBD hate unbundling — the pay-TV package deal had underpinned their huge profits for decades. But cable and satellite “cord cutting” is now inexorable. Narrowly tailored products such as Venu — however suboptimal — are then their only hope to survive in a world where customers demand à la carte entertainment options.

Fubo went public in 2020. Like classic disrupters, it is unburdened by legacy business models. But, while innovative, its business is yet to prove sustainable as its also lacks the strong cash flows that still emanate from old-school media.

Disney, Fox and WBD may eventually be forced by the courts to sell ESPN and their other sports networks as standalone products to Fubo and others. But it is not obvious that the maths will work out for any of them.

>>> US Research Calls I

Research Calls I
  • Upgrades:
    • Banco Bradesco (BBD) upgraded to Buy from Neutral at Goldman; tgt raised to $3.20
    • Burlington Stores (BURL) upgraded to Buy from Hold at Gordon Haskett; tgt $300
    • Gates Industrial (GTES) upgraded to Outperform from Sector Perform at RBC Capital Mkts; tgt raised to $22
    • Taylor Morrison Home (TMHC) upgraded to Buy from Neutral at BTIG Research; tgt $78
  • Downgrades:
    • Dutch Bros (BROS) downgraded to Neutral from Overweight at Piper Sandler; tgt lowered to $36
    • HP Inc. (HPQ) downgraded to Equal-Weight from Overweight at Morgan Stanley
    • Terran Orbital (LLAP) downgraded to Neutral from Buy at H.C. Wainwright; tgt lowered to $0.25
    • Shake Shack (SHAK) downgraded to Neutral from Overweight at Piper Sandler; tgt lowered to $114
    • Sol-Gel (SLGL) downgraded to Outperform from Strong Buy at Raymond James; tgt lowered to $4
  • Others:
    • Aligos Therapeutics (ALGS) initiated with a Buy at H.C. Wainwright; tgt $75
    • Foghorn Therapeutics (FHTX) initiated with an Outperform at Evercore ISI; tgt $20
    • Lineage (LINE) initiated with a Neutral at UBS; tgt $88
    • Lineage (LINE) initiated with a In-line at Evercore ISI; tgt $88
    • Lineage (LINE) initiated with a Sector Outperform at Scotiabank; tgt $95
    • Lineage (LINE) initiated with a Buy at Truist; tgt $94
    • Lineage (LINE) initiated with an Equal Weight at Wells Fargo; tgt $86
    • Lineage (LINE) initiated with an Overweight at Morgan Stanley; tgt $100
    • Lineage (LINE) initiated with an Outperform at Robert W. Baird; tgt $91
    • Lineage (LINE) initiated with a Neutral at Mizuho; tgt $86
    • Lineage (LINE) initiated with an Overweight at JP Morgan; tgt $93
    • Lineage (LINE) initiated with a Buy at Goldman; tgt $105
    • NVIDIA (NVDA) reiterated with a Buy at Goldman; tgt $135
    • OneStream (OS) initiated with an Outperform at Raymond James; tgt $32
    • OneStream (OS) initiated with a Buy at Truist; tgt $35
    • OneStream (OS) initiated with a Sector Outperform at Scotiabank; tgt $34
    • OneStream (OS) initiated with an Outperform at Wolfe Research; tgt $32
    • OneStream (OS) initiated with an Equal-Weight at Morgan Stanley; tgt $29
    • OneStream (OS) initiated with a Buy at BTIG Research; tgt $37
    • OneStream (OS) initiated with a Neutral at Citigroup; tgt $34
    • OneStream (OS) initiated with an Overweight at JP Morgan; tgt $30
    • Predictive Oncology (POAI) initiated with a Buy at H.C. Wainwright; tgt $3
    • Pure Storage (PSTG) initiated with a Neutral at Piper Sandler; tgt $60
    • Rubrik (RBRK) initiated with an Overweight at Piper Sandler; tgt $42
    • Skyward Specialty Insurance Group (SKWD) initiated with an Outperform at William Blair

>>> US Early premarket gappers

Early premarket gappers
  • Gapping up:
    • XPER +18.1%, FUBO +11.1%, BNR +8.4%, CVII +6.3%, AMD +2.9%, PL +2%, GLAD +1.2%, HTGC +1%, SAMG +0.8%, CBOE +0.5%
  • Gapping down:
    • LQDA -32.7%, RILY -8.5%, EL -8.4%, SOND -4.6%, VCEL -1.9%, AGRO -1.8%, KEN -1.3%, EDU -1.1%

>>> Europe : Brokers Upgrades & Downgrades - 19th of August 2024 V3(++)

>>> Up
* ArcelorMittal Raised to Overweight at Barclays; PT 25 euros
* Aryzta Raised to Buy at Bank Vontobel; PT 2.30 Swiss francs
* Bradesco ADRs Raised to Buy at Goldman; PT $3.20 (+)
* Coca-Cola Femsa ADRs Raised to Outperform at Itau BBA; PT $101
* Demant AS raised to Hold from Reduce at Kepler Cheuvreux PT DKK20
* Ebro Foods Raised to Outperform at Grupo Santander
* ForFarmers raised to Hold from Reduce at Kepler Cheuvreux, PT Euro 3
* Holcim raised to Buy from Hold at Deutsche Bank, PT CH91
* Kesla Raised to Reduce at Inderes; PT 3.80 euros
* Martela Raised to Reduce at Inderes; PT 1 euro
* Nexstim Raised to Accumulate at Inderes; PT 3.40 euros (++)
* NIBE Industrier Raised to Hold at ABG; PT 50 kronor
* NIBE Industrier Raised to Accumulate at Inderes; PT 53 kronor (+)
* Seplat Energy Raised to Buy at Vetiva Capital Management Ltd (++)
* Travis Perkins Raised to Add at Peel Hunt; PT 980 pence

>>> Down
* Argenx Cut to Accumulate at KBC Securities; PT 530 euros (+)
* Avance Gas Cut to Sell at Arctic Securities; PT 128 kroner
* Emmi Cut to Hold at Bank Vontobel; PT 930 Swiss francs
* HP Inc Cut to Equal-Weight at Morgan Stanley; PT $37
* Himalaya Shipping Cut to Sell at DNB Markets; PT 67 kroner (+)
* K+S PT Cut to 10 euros from 12 euros at UBS (++)
* Karnell Group Cut to Hold at SEB Equities; PT 54 kronor
* Mobilezone Cut to Hold at Research Partners (+)
* Nexans Cut to Neutral at Goldman; PT 117 euros (+)
* OSB Group Cut to Hold at Peel Hunt; PT 395 pence
* Ovaro Kiinteistosijoitus Cut to Reduce at Inderes; PT 4.40 euros
* PNE AG Cut to Hold at SMC Research; PT 14.80 euros (++)
* Scatec Cut to Hold at SEB Equities; PT 86 kroner
* Vestas cut to Hold from Buy at Kepler Cheuvreux, PT DKK 175

>>> Initiation
* Holmen Rated New Equal-Weight at Barclays; PT 390 kronor
* IPC Rated New Hold at Fearnley; PT 145 kronor (+)
* Vitec Software Group Rated New Buy at Pareto Securities (++)

>>> Call
* ArcelorMittal Rises; Barclays Upgrades on Attractive Entry Point (++)
* Goldman Sachs Strategists See Consensus on US Margins Too High (+)
* Hedge Funds Buy Stocks as Growth Concerns Ease: Goldman Sachs
* HP Inc. Downgraded at Morgan Stanley on Limited Valuation Upside
* Deutsche Bank Strategists Say Equity Positioning Rises Again (++)
* OSB Rating, Estimates Cut at Peel Hunt After Outlook Lowered
* Travis Perkins Upgraded at Peel Hunt on Confidence in Recovery

FT : US military-civil fusion creates risks as well as rewards

US military-civil fusion creates risks as well as rewards
Venture capital investors and high-tech start-ups are discovering an appetite for the defence sector

The symbolism could hardly be starker. Two American astronauts, who flew to the International Space Station in June on a Boeing Starliner spacecraft, may be stuck in space for months because their return vehicle has sprung a leak in its propulsion system. Nasa is now considering whether a SpaceX Dragon spacecraft can pick them up in February. 

This unhappy incident highlights the extent to which the innovative, private space company run by the maverick Elon Musk has gained primacy over the problem-plagued, 108-year-old government contractor, in spite of Boeing’s glorious history in the US space programme. It is a lesson unlikely to be lost on the Pentagon as it allocates its $800bn-plus budget in future. Like Nasa, the US Department of Defense relies increasingly on a new generation of Silicon Valley start-ups to sharpen its edge. Traditional defence contractors, including Boeing, Raytheon, Lockheed Martin and General Dynamics, known as the primes, are being disrupted.

This month, one of the highest-profile of those disrupters, Anduril Industries, raised $1.5bn from venture capital investors, valuing the company at $14bn. Anduril will now build out Arsenal-1, a state-of-the-art factory to “hyperscale” the production of thousands of autonomous combat drones as part of the Pentagon’s Replicator programme. This initiative aims to deploy thousands of autonomous systems within 18 to 24 months.

Anduril was founded in 2017 by Palmer Luckey, who made a fortune from selling his virtual reality start-up Oculus to Facebook and is now intent on reimagining the defence industry. This year, Luckey told the FT that Anduril’s (immodest) aim was to “save western civilisation”. It would also save taxpayers billions of dollars a year. “The intent is to go toe to toe with the major primes and try to fight our way to an equal footing,” he said.

Russia’s full-scale invasion of Ukraine in 2022 and tensions with China have led to renewed scrutiny of US military preparedness. The use of cheap, effective drones by Ukrainian and Russian forces and the vulnerability of traditional hardware have riveted the attention of defence chiefs. Would one more aircraft carrier or 18,000 drones be more effective in defending Taiwan?

The Pentagon’s critics argue that US technological supremacy has been compromised by its failure to embrace the potential of modern software, cloud computing, commercial space and artificial intelligence quickly enough. “It’s a story of the US getting ambushed by the future,” according to Christian Brose, former staff director at the Senate Armed Services Committee, who is now Anduril’s chief strategy officer.

VC firms, which had long steered clear of defence tech, are also rediscovering an appetite for the sector. Having the Pentagon as a massive customer of first resort certainly adds to the appeal. According to PitchBook, VCs invested more than $120bn globally in the defence sector over the past three years, even though this has slowed this year. 

On a lesser scale, defence tech is taking off in Europe. In July, the German AI defence start-up Helsing raised €450mn at a valuation of almost €5bn. Nato has launched a €1bn Europe-focused innovation fund to promote defence start-ups as well as the Diana accelerator programme. The European Investment Fund, the EU’s private finance wing, has prioritised defence investments. But a big drawback for European start-ups is the fragmentation of national defence procurement. “Europe is very good on the supply side but not very good on the demand side,” says a European policymaker, supporting the creation of a European Iron Dome-style air defence system. “If we were to provide such a demand signal it would be transformative.”

In their book Unit X, Raj Shah and Christopher Kirchhoff describe the cultural battles they fought with the Pentagon to change “the largest and possibly most bureaucratic organisation” in the world with its roughly 3mn employees. In 2015, Ash Carter, then US defence secretary, created the Defense Innovation Unit Experimental (DIUx) to deliver commercial innovations to the military and asked the two authors to lead the effort.

In a video interview, Shah, a former F16 fighter pilot now managing partner of the VC firm Shield Capital, says it was difficult to get serious venture capital investors interested in defence in 2016. “Now it’s the exact opposite. There really has been a sea change here in Silicon Valley. We’ve all watched the invasion of Ukraine with absolute horror.”

But Shah accepts that the reliance on start-ups creates “new dependencies”. He also flags the risk of bubbles and busts in VC investment cycles, meaning the government might have less control over the “R&D spigot” in future.

Luckey and Musk have been outspoken supporters of Donald Trump, which may stir some political sensitivities with any future Democratic administration. Given his significant business interests in China with Tesla, how would Musk’s satellite communications service Starlink respond to an attack on Taiwan?

The Chinese Communist party’s strategic priority is to create world-class armed forces through “military-civil fusion”. Although very different in conception and execution, the US version of military-civil fusion offers a good shot at reasserting military supremacy. But the more dynamic military-technological complex that is emerging carries new risks and vulnerabilities, too.